Ask about this productRelated genes to: LPXN antibody
- Gene:
- LPXN NIH gene
- Name:
- leupaxin
- Previous symbol:
- -
- Synonyms:
- LDPL
- Chromosome:
- 11q12.1
- Locus Type:
- gene with protein product
- Date approved:
- 2000-11-28
- Date modifiied:
- 2014-11-19
Related products to: LPXN antibody
Related articles to: LPXN antibody
- Macrophage M2 polarization plays a pivotal role in breast cancer development. The present study aimed to investigate the interplay of the Leupaxin (LPXN)/HDAC6/EGR2 axis in breast cancer and its impact on macrophage M2 polarization. Our findings indicate that LPXN overexpression in breast cancer tissues correlates with M2 macrophage polarization. To investigate LPXN's potential role, we conducted siRNA-mediated silencing in macrophages. In a breast cancer cell-macrophage co-culture system, LPXN silencing was associated with reduced cancer cell proliferation, decreased M2 polarization markers, and diminished HDAC6 expression. BIOGRD and experimental data suggest a regulatory relationship between LPXN and HDAC6. Notably, HDAC6 inhibition partially reversed the pro-M2 effects of LPXN overexpression. Further mechanistic studies revealed that HDAC6 interacts with EGR2, functioning as its deacetylase and negatively regulating EGR2 expression. EGR2 silencing partially attenuated the anti-M2 effects observed with LPXN knockdown. In murine breast cancer models, LPXN silencing was linked to increased M1 macrophage markers and reduced tumor burden. These findings suggest LPXN may influence breast cancer progression through HDAC6/EGR2-mediated regulation of macrophage polarization. In conclusion, our study demonstrated that the LPXN/HDAC6/EGR2 axis promotes breast cancer progression by augmenting macrophage M2 polarization. - Source: PubMed
Publication date: 2025/11/25
He ShaozhongWang QunHe JiayiChen ZhongyongXiao Yumei - Lung cancer, specifically non-small cell lung cancer (NSCLC), is a leading cause of cancer-related mortality worldwide. TP53, a crucial tumor suppressor gene, is often mutated in various cancers, including lung cancer. This study focuses on the differences in transcriptomic profiles between TP53-mutated (TP53+) and TP53-wildtype (TP53-) NSCLC tumor samples, aiming to develop a gene signature that can predict overall survival and immune response, particularly in the context of immunotherapy. It aims to identify differentially expressed genes (DEGs) associated with TP53 status in non-small cell lung cancer and develop a gene signature that can predict overall survival and immune response. - Source: PubMed
Publication date: 2025/08/08
Xie MiaoLiu BaoguangChen ZiyiCao TongtongZhang Xiaoyan - Metastasis is the main cause of cancer-related deaths, yet the underlying mechanisms remain elusive. Here, using clear cell renal cell carcinoma (ccRCC), a tumor type with frequent lung metastases, we conduct an in vivo genome-wide CRISPR-Cas9 screen and identify HLF as a potent suppressor of lung metastasis. HLF depletion enhances ccRCC cell migration and lung metastasis, whereas HLF overexpression abrogates these effects. In ccRCC patients, HLF expression is reduced at metastatic sites and associates with epigenetic silencing mediated by the SWI/SNF ATPase subunit BRG1. HLF levels negatively correlate with migration potential in collagen. Mechanistically, HLF regulates LPXN expression, modulating the integration of collagen's mechanical cues with the actin cytoskeleton through Paxillin, thereby suppressing cancer cell migration and lung metastasis. Overexpression of HLF or pharmacological inhibition of BRG1 reduces cell invasion across multiple cancer types. Our findings suggest that targeting the BRG1-HLF axis offers a promising therapeutic strategy for combating metastatic cancers. - Source: PubMed
Publication date: 2025/06/05
Zhou JinHepperla AustinSimon Jeremy MKim KangsanHu QingZhang ChuanhaiDong LeiHu LianxinZhang ChengLiao ChenghengFang AliceAdachi YayoiFu HaoyongWang TaoLiang QianZhao FangzhouLiu HongyiTakeda MasashiFang JunZhong HuaLy PeterWang LuKapur PayalXu LinJia LiweiMalladi SrinivasBrugarolas JamesSimon M CelesteLi BoZhang Qing - To identify DNA methylation markers related to clear cell renal cell carcinoma (ccRCC) prognosis and construct a prognostic model. - Source: PubMed
Publication date: 2025/05/26
Li XuwenWang HaoxiLi YajianZhu YihaoZhai YaboXing NianzengYe XiongjunYang Feiya - As the primary source of glucose during fasting, hepatic gluconeogenesis is rigorously regulated to maintain euglycemia. Abnormal gluconeogenesis in the liver can lead to hyperglycemia, a key diagnostic marker and the primary pathological contributor to type 2 diabetes (T2D) and metabolic disorders. Hepatic nuclear factor-4 (HNF4α) is an important regulator of gluconeogenesis. In this study, we identify leupaxin (LPXN) as a novel coactivator for HNF4α. Although previous studies have shown that LPXN is highly correlated with cancer types such as B-cell differentiation and hepatocellular carcinoma progression, the role of LPXN in gluconeogenesis remains unknown. - Source: PubMed
Publication date: 2024/11/26
Luo XiaominLiu FangZhu LijunLiu CaizhiShen RuhuiDing XiaoyinWang YufanTang XiaofangPeng YongdeZhang Zhijian